S&P Futures
6,017.50 +30.50 (+0.51%) Dow Futures
44,702.00 +307.00 (+0.69%) Nasdaq Futures
20,967.50 +117.75 (+0.56%) Russell 2000 Futures
2,438.60 +25.00 (+1.04%) Crude Oil
71.07 -0.17 (-0.24%) Gold
2,688.40 -23.80 (-0.88%)
Idorsia Ltd (IDRSF)
- GlobeNewswire
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, will be presented at the American Heart Association (AHA) annual Scientific Sessions 2024, taking place in Chicago, Illinois, November 16–18, 2024. AHA Scientific Sessions is the preeminent conference of its kind featuring top global leaders in cardiovascular and brain health. On
- GlobeNewswire
Idorsia announces financial results for the first nine months of 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net revenue 9M 2024 at CHF 53 million.US GAAP operating loss 9M 2024 of CHF 154 million and Non-GAAP operating loss of CHF 248 million.Improved Guidance for 2024, driven by diligent cost control.QUVIVIQ™ (daridorexant) total net sales of CHF 39 million in 9M 2024.Commercial partnership for QUVIVIQ with Men
